GSK-3β resulted the only target gene satisfying the above-mentioned selection criteria, so we used CHIR99021, a selective inhibitor of GSK-3α/β, to investigate whether it could represent a suitable drug for the treatment of epithelioid sarcoma. This evidence concerns the gene GSK3B and epithelioid sarcoma.